Impaired immunity against tetanus in Type 2 Diabetes

Basit Öğe Kaydı
dc.authoridKARABAY, OGUZ/0000-0003-1514-1685
dc.authoridSelam, Belgin/0000-0003-4478-7514
dc.contributor.authorTamer, A
dc.contributor.authorKarabay, O
dc.contributor.authorEkerbicer, H
dc.contributor.authorTahtaci, M
dc.contributor.authorSelam, B
dc.contributor.authorCelebi, H
dc.date.accessioned2024-09-25T20:00:07Z
dc.date.available2024-09-25T20:00:07Z
dc.date.issued2005
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractBackground: The aim of this study was to compare serum levels of tetanus antibody in diabetic patients over 50 years of age with those of age-and sex-matched non-diabetic controls. Material/Methods: The study population consisted of 115 type 2 diabetic patients and 115 age-and sex-matched nondiabetic patients. Serum levels of tetanus IgG were measured by a commercial ELISA kit, and levels over 0.1 IU/ml were considered protective. Results: Mean serum levels of tetanus antibody in the diabetic and control groups were 0.164 +/- 0.140 IU/ml vs. 0.374 +/- 0.534 IU/ml, respectively (p < 0.001). Mean serum levels of tetanus antibody in the diabetics vs. controls aged 50-64 years were 0.172 +/- 0.141 IU/ml vs. 0.568 +/- 0.653 IU/ml and in those >= 65 years 0.151 +/- 0.139 IU/ml vs. 0.154 +/- 0.193 IU/ml, respectively (p < 0.001, p=1.000). Among patients aged 50-64 years, 38 (55.9%) cases in the diabetic and 45 (73.8%) in the control group demonstrated protective levels of tetanus antibodies (p=0.034). Of patients >= 65 years, 24 (51.1%) cases in the diabetic and 22 (40.7%) in the control group had protective levels of tetanus antibodies (p=0.298). Conclusions: Serum levels of tetanus antibody decreased in diabetic patients older than 50 years of age, whereas this period of time is prolonged to 65 years in healthy individuals. All individuals over 65 years should be vaccinated against tetanus; however, vaccination over 50 years of age might be considered for diabetic patients.en_US
dc.identifier.endpageCR584en_US
dc.identifier.issn1643-3750
dc.identifier.issue12en_US
dc.identifier.pmid16319789en_US
dc.identifier.startpageCR580en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/14071
dc.identifier.volume11en_US
dc.identifier.wosWOS:000234268500013en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherInt Scientific Information, Incen_US
dc.relation.ispartofMedical Science Monitoren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzYK_20240925en_US
dc.subjecttetanusen_US
dc.subjectType 2 Diabetesen_US
dc.subjectClostridium tetanien_US
dc.titleImpaired immunity against tetanus in Type 2 Diabetesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu